Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse MKT  >  IGI LABORIGI       

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2016 65,7 M
EBIT 2016 1,16 M
Net income 2016 -10,3 M
Debt 2016 54,5 M
Yield 2016 -
Sales 2017 95,4 M
EBIT 2017 14,2 M
Net income 2017 -1,04 M
Debt 2017 62,8 M
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales2016 7,56x
EV / Sales2017 5,30x
Capitalization 443 M
More Financials
Company
Teligent, Inc. develops, manufactures and markets topical formulations.The company sells generic topical pharmaceutical products under IGI label.It also provides development, formulation, and manufacturing services to the pharmaceutical, over-the-counter and cosmetic markets.The company's products... 
Sector
Pharmaceuticals
Calendar
07/28Earnings Release
More about the company
Surperformance© ratings of IGI LABORIGI
Trading Rating : Investor Rating :
More Ratings
Latest news on IGI LABORIGI
07/19 TELIGENT : Advances $50 Million Facility Expansion
07/13 TELIGENT, INC. : To Hold Conference Call For 2nd Quarter 2016 Results
07/12 TELIGENT : holds groundbreaking for major expansion project
07/08 TELIGENT, INC. : Receives Two FDA Approvals For Topical Prescription Portfolio
07/06 TELIGENT, INC. : Advances $50 Million Facility Expansion
07/06 TELIGENT : Advances $50 Million Facility Expansion
06/27 TELIGENT : stock price target held steady to $0 as covered today by Raymond Jame..
06/21 TELIGENT, INC. : To Present At JMP Securities Life Sciences Conference On June 2..
05/27 TELIGENT, INC. : Change in Directors or Principal Officers, Submission of Matter..
05/17 TELIGENT : Gains More Than 2% FDA Approves ANDA For Triamcinolone Ointment
More news
Sector news : Pharmaceuticals - NEC
07/22DJJOHNSON & JOHNSON : Acclarent Unit in $18 Million U.S. Settlement
07/22DJJOHNSON & JOHNSON : Acclarent Unit in $18 Million U.S. Settlement
07/22DJBAYER : 2Q 2016 -- Forecast
07/22DJMonsanto Wins EU Nod for New Biotech Soybeans
07/21DJBIOGEN : Announces CEO Search, Lifts Guidance--2nd Update
More sector news : Pharmaceuticals - NEC
Advertisement
Chart IGI LABORIGI
Duration : Period :
IGI LABORIGI Technical Analysis Chart | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 9,50 $
Spread / Average Target 14%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Jason Grenfell-Gardner President, Chief Executive Officer & Director
James Charles Gale Chairman
Sanjay Samudre Operations Director
Jenniffer L. Collins CFO, Secretary & Head-Investor Relations
Stephen Richardson Chief Scientific Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
IGI LABORIGI89.51%443
JOHNSON & JOHNSON21.72%343 913
PFIZER INC.13.82%222 823
NOVARTIS AG-5.13%219 526
ROCHE HOLDING LTD.-9.62%218 832
MERCK & CO., INC.11.36%162 815
More Results